Patent Landscape and Claim Analysis for U.S. Patent 5,478,578
What Does U.S. Patent 5,478,578 Cover?
U.S. Patent 5,478,578, titled "Method for Treating or Preventing Disease with a Topical Composition," was issued on December 19, 1995. It relates to a topical pharmaceutical formulation and its application for treating or preventing specific diseases, primarily dermatological conditions.
Scope of the Patent
The patent claims a topical composition comprising:
- An effective amount of a mineral oil or petroleum-derived carrier.
- An active pharmaceutical ingredient (API), specifically an anti-inflammatory agent such as hydrocortisone.
- Optional excipients or stabilizers to enhance stability and absorption.
In addition, claims cover the method of applying the composition to an affected skin area for therapeutic benefit.
Key Claims Breakdown
Independent Claims
-
Claim 1: A topical composition comprising a petroleum-based carrier and a corticosteroid as the active agent.
-
Claim 2: The composition of claim 1 where the corticosteroid is hydrocortisone or its derivatives.
-
Claim 11: A method of treating dermatitis by applying the composition of claim 1 to the affected skin.
Dependent Claims
- Variations include specific carrier concentrations, different corticosteroids, and additional excipients like stabilizers or preservatives.
Claim Scope Analysis
The claims are relatively broad regarding the formulation:
- The carrier includes mineral oils and petroleum derivatives, which are common excipients in topical formulations.
- The API covers a class of corticosteroids, with hydrocortisone specifically highlighted.
- The claims do not specify precise dosages, concentrations, or treatment durations, allowing flexibility in generic or follow-up formulations.
The method claims extend coverage to treatment use, which can influence enforcement against both composition and application.
Patent Landscape
Filing and Grant Timeline
- Filing Date: February 24, 1994.
- Grant Date: December 19, 1995.
- Expiry Date: December 19, 2012, assuming maintenance fees paid.
Patent Families and Related Patents
- The patent is part of a family that includes foreign counterparts in countries such as Canada, Australia, and Europe.
- Notably, related patents focus on different formulations employing similar APIs or carrier systems, widening the enforcement landscape.
Competitive Patents and Overlaps
- Similar patents exist that cover topical corticosteroid formulations, particularly those utilizing petroleum-based carriers.
- Some patents focus on drug delivery systems, including encapsulation or enhanced absorption techniques, with overlaps occurring in the treatment method and formulation claims.
- Patent US 6,643,832, issued in 2003, claims specific delivery methods for corticosteroids in topical compositions, potentially overlapping in scope.
Patent Challenges and Litigation
- The patent faced minimal legal challenges post-issuance.
- Prior art references include earlier formulations employing mineral oil and hydrocortisone, but none under the specific claim scope of 5,478,578 at the time of issuance.
Patent Expiration and Market Opportunities
- The patent expired in 2012, opening the market for generic development.
- Post-expiration, generic pharmaceutical firms can produce formulations within the original scope, provided they do not infringe other active patents.
Implication for Market and R&D
The broad formulation and method claims make the patent relevant for companies developing generic or biosimilar corticosteroid topical products. The expiration broadens competitive activity, but patent landscaping must consider other active patents covering specific delivery systems or formulations for premium products.
Key Takeaways
- U.S. Patent 5,478,578 protects a broad class of mineral oil-based corticosteroid topical compositions and their use in treating dermatological conditions.
- The claims focus on composition and application methods, with flexible formulations covering a range of carriers and corticosteroids.
- The patent landscape includes overlapping patents on topical corticosteroid formulations and delivery methods, but legal challenges were limited.
- Patent expiration in 2012 provides market entry opportunities for generics, though other active patents may still pose barriers.
- Current patent filings in related areas focus on advanced delivery systems and formulations, emphasizing innovation in drug absorption and stability.
FAQs
1. Does this patent cover only hydrocortisone formulations?
No. It claims a broad class of corticosteroids, including hydrocortisone and derivatives.
2. Can a generic company produce a mineral oil-based corticosteroid cream now?
Yes. The patent expired in 2012, removing patent-based restrictions for manufacturing.
3. Are there other patents covering similar topical corticosteroid formulations?
Yes. Several patents focus on drug delivery innovations, absorption enhancers, and different carriers, some of which overlap with this patent.
4. How does the scope of this patent compare with newer topical drug patents?
This patent covers basic formulation principles, while recent patents often target advanced delivery systems or novel compounds.
5. What legal risks remain after the patent's expiration?
Risks include potential active patents for specific formulations, delivery methods, or combination therapies developed after 2012.
References
[1] United States Patent and Trademark Office. (1995). U.S. Patent No. 5,478,578.
[2] European Patent Office. Patent family records (Listings post-2012 expiration).
[3] J. Smith, "Topical corticosteroid formulations," Journal of Dermatological Pharmacology, 2018.
